GNI Group forecasts record 28.7bn yen revenue amid strategic shifts

GNI Group projects 28.7 billion yen revenue and 23.2 billion yen operating profit for fiscal year ending December 2025, a substantial increase from 2024.

Growth is driven by the medical device segment's strong performance, with revenue increasing 59.1% to 3.9 billion yen in Q2 2025.

In July 2025, the company raised 12.5 billion yen through an overseas stock offering, allocating 40% to acquire additional Gyre Pharmaceuticals shares and 50% for medical device M&A.

Drug discovery subsidiary Cullgen is progressing toward a NASDAQ listing, with potential valuation gains of 19.2 billion yen upon listing.